David Guebert, the chief financial officer of Mindmed Inc. (NASDAQ: MNMD) (NEO: MMED) is set to retire from his position at the last day of this month i.e. March 31st. This announcement was made by the company’s director and chief executive officer, Robert Barrow.
“On behalf of the Board of Directors and Executive team, I would like to thank Dave, who was essential to the founding and early growth of our organization. As we advance our robust drug development and digital medicine programs, we continue to identify leaders who will guide MindMed through this critical stage in our growth. Dave leaves us well positioned financially and strategically to create long-term value for shareholders and to deliver on our commitment to patients in need of novel treatment options,” said Barrow.
MindMed is a psychedelic medicine biotechnology company which develops psychedelic-inspired medicine and therapies to treat addiction and mental illness. The company has retained an executive search firm to assist its board of directors in sourcing the new chief financial officer who possess the required skills and experience for the post.
